https://www.selleckchem.com/pr....oducts/shp099-dihydr
9% and 70.0% (P=0.311), and the incidences of grade Ⅲ-Ⅴ including myelosuppression were 36.4% and 10.0% (P=0.311), gastrointestinal reaction were 9.1% and 10.0%, (P=1.00 and other immune-related adverse events were 18.2% and 30.0% (P=1.00. Further analysis showed the metastatic number (P=0.006), platinum sensitivity (P=0.036) and LDH level (P=0.022) significantly affected the ORR of olaparib/pembrolizumab therapy. Conclusion Our preliminary study indicates that olaparib combined with pembrolizumab is an efficient and
Like
Comment
Share
